MiMedx Group (MDXG) AI Stock Analysis

• Market Cap: $979.27M
• Dividend Yield: N/A
• Average Volume (3M): 776.83K
• Price to Earnings (P/E): 24.6
• Beta (1Y): 0.77
• Revenue Growth: 5.34%
• EPS Growth: -50.52%
• Country: US
• Employees: 837
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): 0.05
• Shares Outstanding: 147,702,130
• 10 Day Avg. Volume: 649,994
• 30 Day Avg. Volume: 776,828
• PEG Ratio: -7.04
• Price to Book (P/B): 4.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 81.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 76 Outperform
• Price Target: $8.50 ▲( 28.21% Upside)

MiMedx Group's overall stock score reflects its strong financial fundamentals, including revenue growth and improved profitability. While technical analysis shows mixed signals, the company's strategic initiatives and positive earnings call guidance support a growth outlook. Valuation appears fair, but further upside may require additional growth drivers. Challenges in specific segments, like wound care and Medicare reimbursement, present risks but are being addressed strategically.

Positive Factors

Product Sales

MDXG put up another quarter of strong product sales, with $93mn of revenue versus $89.4mn Street, or 7% growth versus 3% expectation.

Strategic Initiatives

Management remains optimistic about current strategic initiatives, with the recent launch of HELIOGEN expected to contribute meaningfully.

Negative Factors

Reimbursement Uncertainty

Continuing reimbursement uncertainty disrupted the business in the physician office setting.

MiMedx Group Business Overview & Revenue Model

Company Description

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

How the Company Makes Money

MiMedx Group generates revenue primarily through the sale of its regenerative biologics products to healthcare providers, hospitals, and clinics. The company markets its products to physicians and healthcare facilities that utilize them in various medical applications, such as wound care and orthopedic procedures. Key revenue streams include direct sales, distributor agreements, and partnerships with healthcare organizations. Additionally, MiMedx invests in research and development to expand its product offerings and enhance its technology, which contributes to its earnings by meeting evolving market demands and maintaining a competitive edge in the regenerative medicine sector.

MiMedx Group Financial Statement Overview

Summary

MiMedx Group has shown strong growth in revenue and profitability, with a positive net profit margin and robust cash flow. The solid balance sheet with low leverage supports financial stability, though opportunities to leverage cash reserves more effectively could boost growth.

Income Statement

MiMedx Group has shown strong growth in revenue over the observed periods, with a notable increase from $267.8M in 2022 to $352.4M in TTM (Trailing-Twelve-Months) 2025. Gross profit margin is robust at 81.9% for TTM, indicating efficient cost management. The net profit margin has turned positive, reaching 11.4% in TTM 2025 from negative figures in previous years, signaling improved profitability. However, the decline in EBIT from 2024 to TTM 2025 suggests some operational cost challenges.

Balance Sheet

The company's balance sheet reflects a solid equity position with an equity ratio of 74.98% in TTM 2025, indicating a strong capital structure. The debt-to-equity ratio is very low at 0.01, showcasing minimal leverage, which reduces financial risk. Return on equity is positive at 19.81%, reflecting efficient use of equity to generate profits. Nonetheless, the high level of cash reserves relative to debt suggests missed opportunities for investment or growth.

Cash Flow

MiMedx Group demonstrates strong cash flow generation with free cash flow growing significantly, highlighted by a free cash flow of $68.7M in TTM 2025. The operating cash flow to net income ratio is favorable, indicating efficient cash generation from operations. Furthermore, the free cash flow to net income ratio of 1.71 signifies robust cash conversion efficiency. Overall, the cash flow position is solid, underpinning financial stability and flexibility.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
352.38M	348.88M	321.48M	267.84M	258.62M	248.23M
	Gross Profit
288.54M	288.81M	266.84M	219.53M	215.33M	208.90M
	EBIT
53.92M	58.87M	37.12M	-24.97M	-5.00M	-44.37M
	EBITDA
54.95M	64.34M	40.52M	-10.69M	-1.89M	-45.76M
	Net Income Common Stockholders
40.18M	42.42M	67.44M	-30.20M	-10.29M	-49.28M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
106.43M	104.42M	82.00M	65.95M	87.08M	95.81M
	Total Assets
270.42M	263.92M	239.05M	171.43M	187.93M	202.03M
	Total Debt
18.66M	18.83M	48.10M	48.59M	48.13M	47.70M
	Net Debt
-87.77M	-85.59M	-33.90M	-17.36M	-38.96M	-48.12M
	Total Liabilities
67.64M	70.81M	96.33M	189.42M	187.85M	202.18M
	Stockholders Equity
202.78M	193.11M	142.72M	-17.99M	82.00K	-150.00K
Cash Flow		Free Cash Flow
68.32M	64.52M	24.79M	-20.58M	-5.45M	-34.82M
	Operating Cash Flow
67.55M	66.20M	26.77M	-17.89M	-1.98M	-30.26M
	Investing Cash Flow
-3.96M	-9.58M	-2.15M	-2.66M	-3.40M	-4.55M
	Financing Cash Flow
-3.61M	-34.20M	-8.57M	-580.00K	-3.35M	61.56M

MiMedx Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Negative. The current price of 6.63 is below the 20-day moving average (MA) of 6.90, below the 50-day MA of 7.15, and below the 200-day MA of 7.51, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 41.55 is Neutral, neither overbought nor oversold. The STOCH value of 7.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDXG.

MiMedx Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	76 Outperform	$979.27M	24.58	22.29%	―	5.34%	-50.52%
ARDX	57 Neutral	$949.84M	―	-36.26%	―	127.33%	21.31%
Sector *	53 Neutral	$5.14B	3.23	-45.01%	2.85%	17.55%	-0.69%
LQDA	50 Neutral	$1.31B	―	-188.03%	―	-11.42%	0.26%
CLDX	50 Neutral	$1.35B	―	-23.20%	―	24.49%	5.14%
OCUL	47 Neutral	$1.16B	―	-57.19%	―	-0.33%	-3.59%
IOVA	39 Underperform	$594.40M	―	-51.85%	―	11070.12%	32.07%

MiMedx Group Corporate Events

MiMedx Group Highlights Growth at Healthcare Conference

MiMedx Group announced its participation in the Bank of America Securities 2025 Healthcare Conference, highlighting its updated investor presentation. The company is poised for growth with expectations of expanding its product portfolio and increasing its presence in surgical settings, driven by favorable market trends and innovative placental-derived products. The announcement underscores MiMedx’s strategic focus on expanding its global footprint and enhancing its product offerings to drive profitability and stakeholder value.

The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.

MiMedx Group Reports Q1 2025 Financial Results

On April 30, 2025, MiMedx Group announced its first quarter financial results, reporting net sales of $88 million, a 4% increase year-over-year, driven by significant growth in surgical products. Despite a decline in wound product sales and a decrease in gross margin, the company maintained a strong adjusted EBITDA margin of 20%. CEO Joseph H. Capper highlighted the company’s strategic efforts to address challenges in the Medicare landscape and expand their product pipeline, including the introduction of CELERA™. MiMedx remains focused on long-term growth, expecting high single-digit sales growth for 2025 and low double-digit growth in subsequent years.